- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01907074
Quantitative Liver Function Tests Using Cholates
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study involves using the dual cholate test as our quantitative liver function test of choice. Clearance of the oral cholate provides an assessment of portal blood flow. Clearance of the intravenous (IV) cholate provides an assessment of the systemic blood flow. The ratio of these clearances indicates the fraction of cholate that is shunted to the systemic circulation, and is called the cholate shunt fraction.2
This study will measure cholate elimination rate constant (cholate Kelim), clearance of orally administered cholate, clearance of intravenously administered cholate and cholate shunt. This study will compare the presence and extent of the cholate clearances and shunt fraction with the presence and extent of hepatic fibrosis and portal hypertension (as measured by a hepatic venous pressure gradient [HVPG] procedure.)
The patients who will be enrolled in this study may or may not be those who are undergoing clinically indicated hepatic venous pressure gradient (HVPG) measurements at Baylor University Medical Center, with or without a liver biopsy. Patients having the HVPG measurements will be admitted to Baylor University Medical Center (BUMC) and prepared in the routine clinical fashion for their clinically-indicated HVPG measurement. The cholate test, including blood draws, will be performed after the HVPG procedure. The cholate test may also be performed in the Hepatology clinic
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- End-stage liver disease patient or Living Liver Donor or Congenital Heart Disease patients
- Age: 18 yr to 80 yr
- Patients or Legal Authorized Representative (LAR) must provide written consent and be willing and able to adhere to study requirements
- Stage 3-4 fibrosis by METAVIR score or clinical evidence of advanced fibrosis (End-stage liver disease patients only)
Exclusion Criteria:
- Hepatic encephalopathy Grade 3 or 4
- Pregnancy or intent to become pregnant
- Subjects with inability to provide consent for one's self
- Subjects with a life expectancy < 1 year
- Subjects who have participated in an investigational drug study within the past 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cholates Compound
|
Cholates is given intravenously (IV push) and by mouth, once per study visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the effectiveness and accuracy of quantitative liver function testing using oral and IV cholate in patients with end-stage liver disease OR in patients who donate a portion of their liver
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare presence and extent of the cholate clearances
Time Frame: One year
|
One year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Annual tests to measure changes in liver function
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Trotter, MD, Baylor Health Care System
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 011-063
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Liver Disease
-
Vanderbilt University Medical CenterEnrolling by invitationEnd Stage Liver DIseaseUnited States
-
Virginia Commonwealth UniversityCompletedEnd Stage Liver DIseaseUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonCompletedEnd-stage Liver DiseaseUnited Kingdom
-
Proteonomix, Inc.University of Medicine and Dentistry of New Jersey; NumodaUnknownEnd Stage Liver DIseaseUnited States
-
University of ZurichUniversity Ghent; University Hospital of Sao Paulo, BrazilCompleted
-
RenJi HospitalNot yet recruitingEnd Stage Liver DIsease
-
Mayo ClinicRecruiting
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Huashan HospitalRecruiting
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina